Interviews: Biomunex CSO defines lead compounds, early R&D plans
Interviews: Biomunex CEO on earlier deals for cancer drugs
Interviews: Bispecific Antibodies Close in on Cancer (GEN EXLUSIVES)
Press Release: nomination of Dr. Amigorena and Dr. Grabulovski as Key Advisers
Press Release: Biomunex presents novel data on BiXAb® antibodies
Press Release: nomination of the CSO Dr. Zhukovsky
